கிட்நீ வாரம் மறுபரிசீலனை செய்யப்பட்டது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கிட்நீ வாரம் மறுபரிசீலனை செய்யப்பட்டது. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கிட்நீ வாரம் மறுபரிசீலனை செய்யப்பட்டது Today - Breaking & Trending Today

Bayer's Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes

Published: May 10, 2021
May 10, 2021 11:00 UTC
Finerenone significantly reduced the risk of the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care
1
FIGARO-DKD is the second positive Phase III study within the finerenone study program in CKD and T2D to meet its primary endpoint
1,2,3
Bayer’s Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug finerenone versus placebo when added to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has met its primary endpoint. The study showed finerenone significantly reduced the composite risk of time to first occurrence of cardiovascular (CV) death or non-fatal CV events (myocardial infarction, stroke, or hospitalization for heart failure). The Phase III FIGARO-DKD study included more patients with earlier stage CKD and T2D compared t ....

United States , United Kingdom , Luism Ruilope , Bayer Cross , Christian Rommel , Head Of Research , British Medical Journal Open Diabetes Research , Drug Administration , Preventative Medicine Department , International Diabetes Foundation , Public Health , Autonoma University , Kidney Fund , National Kidney Foundation , American Society Of Nephrology , International Diabetes Federation , Preventative Medicine , Executive Committee , Priority Review , American Society , Kidney Week Reimagined , New England Journal , Fast Track , Chronic Kidney Disease , Kidney Disease , Baseline Characteristics ,

As SGLT2 Inhibitors Create Increased Market Complexities for Chronic Kidney Disease Non-Dialysis Patients, How Quickly Will Patient Care Evolve

Share this article
Share this article
EXTON, Pa., March 4, 2021 /PRNewswire/ Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as diabetic complications, hyperkalemia, and metabolic acidosis. At the American Society of Nephrology (ASN) fall 2020 conference, Kidney Week Reimagined, news about SGLT2 inhibitors for CKD patients with
and without diabetes created a stir and caused optimism about potential paradigm shifts for CKD patients.
The fierce competition between AstraZeneca and Vifor/Relypsa in the hyperkalemia market will likely spill into the SGLT2 inhibitor market in 2021, with potential additional complexities surrounding other in-class SGLT2 inhibitors (Eli Lilly/Boehringer Ingelheim s Jardiance and Pfizer/Merck s Steglatro), as well as the much-anticipated diabetic kidney disease (DKD) pipeline agent from Bayer, finerenone. ....

United States , Farxiga Astrazeneca , Invokana Vifor Relypsa Janssen , Kristen Henn , Vifor Relypsa , Novo Nordisk , Merck Steglatro , American Society Of Nephrology , Spherix Network , Business Development , American Society , Kidney Week Reimagined , Boehringer Ingelheim , Realtime Dynamix , Chronic Kidney Disease , Realworld Dynamix , Spherix Global Insights , Time Dynamix , World Dynamix , Global Insights , ஒன்றுபட்டது மாநிலங்களில் , கிறிஸ்டன் கோழி , அமெரிக்கன் சமூகம் ஆஃப் நெப்ராலஜி , வணிக வளர்ச்சி , அமெரிக்கன் சமூகம் , கிட்நீ வாரம் மறுபரிசீலனை செய்யப்பட்டது ,

As SGLT2 Inhibitors Create Increased Market Complexities for Chronic Kidney Disease Non-Dialysis Patients, How Quickly Will Patient Care Evolve

As SGLT2 Inhibitors Create Increased Market Complexities for Chronic Kidney Disease Non-Dialysis Patients, How Quickly Will Patient Care Evolve
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Farxiga Astrazeneca , Invokana Vifor Relypsa Janssen , Kristen Henn , Vifor Relypsa , Novo Nordisk , Merck Steglatro , American Society Of Nephrology , Spherix Network , Business Development , American Society , Kidney Week Reimagined , Boehringer Ingelheim , Realtime Dynamix , Chronic Kidney Disease , Realworld Dynamix , Spherix Global Insights , Time Dynamix , World Dynamix , Global Insights , ஒன்றுபட்டது மாநிலங்களில் , கிறிஸ்டன் கோழி , அமெரிக்கன் சமூகம் ஆஃப் நெப்ராலஜி , வணிக வளர்ச்சி , அமெரிக்கன் சமூகம் , கிட்நீ வாரம் மறுபரிசீலனை செய்யப்பட்டது ,

Bayer announces FDA accepts NDA and grants priority review for Finerenone for patients with CKD and T2D

Bayer announces FDA accepts NDA and grants priority review for Finerenone for patients with CKD and T2D
pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.

United States , Michael Devoy , Bayer Ag Pharmaceuticals Division , American Society Of Nephrology , Company Press , Head Of Medical Affairs Pharmacovigilance , American Society , Kidney Week Reimagined , New England Journal , Medical Affairs , Chief Medical , Priority Review , New Drug Application , ஒன்றுபட்டது மாநிலங்களில் , அமெரிக்கன் சமூகம் ஆஃப் நெப்ராலஜி , நிறுவனம் ப்ரெஸ் , தலை ஆஃப் மருத்துவ வாழ்க்கைத்தொழில்கள் மருந்தியல் , அமெரிக்கன் சமூகம் , கிட்நீ வாரம் மறுபரிசீலனை செய்யப்பட்டது , புதியது இங்கிலாந்து இதழ் , மருத்துவ வாழ்க்கைத்தொழில்கள் , தலைமை மருத்துவ , ப்ரையாரிடீ விமர்சனம் , புதியது மருந்து விண்ணப்பம் ,